Search results
Results from the WOW.Com Content Network
The recommended intravenous dosage in adults is 500 mg every 6 hours or 1000 mg every 12 hours, with modification to achieve a therapeutic range as needed. The recommended oral dosage in the treatment of antibiotic-induced pseudomembranous enterocolitis is 125 to 500 mg every 6 hours for 7 to 10 days. [53]
TMP/SMX is commonly used due to its ability to achieve high concentrations in urinary tract tissues and urine. This antibiotic combination demonstrates notable efficacy in both the treatment and prophylaxis of recurrent urinary tract infections. [12] Common adverse effects include nausea, vomiting, rash,pruritus, and photosensitivity. [26]
A UTI vaccine is a vaccine used for prevention of recurrent urinary tract infections (UTIs). [1] [2] A number of UTI vaccines have been developed and/or marketed.[1] [2] [3] These include Uromune (MV-140; sublingual spray), UroVaxom (OM-89, OM-8980; oral tablet), [4] Solco-Urovac (Strovac; vaginal suppository or intramuscular injection), [5] [6] ExPEC4V (V10, JNJ-63871860; intramuscular ...
Urinary tract infections, bacterial prostatitis, community-acquired pneumonia, bacterial diarrhea, mycoplasmal infections, gonorrhea: Nausea (rare), irreversible damage to central nervous system (uncommon), tendinosis (rare) Inhibits the bacterial DNA gyrase or the topoisomerase IV enzyme, thereby inhibiting DNA replication and transcription ...
Glycopeptide antibiotics are a class of drugs of microbial origin that are composed of glycosylated cyclic or polycyclic nonribosomal peptides.Significant glycopeptide antibiotics include the anti-infective antibiotics vancomycin, teicoplanin, telavancin, ramoplanin, avoparcin and decaplanin, corbomycin, complestatin and the antitumor antibiotic bleomycin.
The risk of UTI recurrence with Uromune treatment has been found to increase with time, suggesting that the vaccine gradually wears off. [ 5 ] [ 6 ] In a 2022 long-term prospective observational study with 1,003 patients, Uromune reduced the number of UTIs to 0–2 in 95.5% at 3 months, in 86.8% at 6 months, and in 54.7% at 12 months. [ 7 ]
Durata Therapeutics acquired the rights to dalbavancin in December 2009, and has initiated two new phase-III clinical trials for treatment of ABSSSIs. [24] Preliminary results in 2012 were promising. [25] About 1,289 adults with ABSSSI were given dalbavancin or vancomycin randomly, and dalbavancin was found to exhibit efficacy comparable to ...
Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. [1] Other uses include for middle ear infections and travelers' diarrhea. [1] With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. [1] [2] It is taken orally (swallowed by mouth). [1]